

YOUR LIFE SCIENCES PARTNER

Ontario is taking life sciences to the next level, tackling some of the biggest challenges the world has ever seen. In the fall of 2024, the province launched the next phase of our life science strategy, investing an additional \$146 million to establish Ontario as a global bio-manufacturing and life sciences hub leading the development, commercialization and early adoption of innovative health products and services.

Since 2018, Ontario's life sciences sector has secured over \$5 billion in investments, attracting prominent global bio-manufacturers such as Sanofi, Roche, AstraZeneca and Moderna. Our diversified sector, collaborative spirit and deep talent pool are creating medical innovations that will improve health care delivery around the globe. Whether you want to expand your operations here or source some of the highest quality medical products and services in the world, Ontario is your life sciences destination.

ONTARIO'S LIFE SCIENCES SECTOR BY THE NUMBERS

OVER **50%**OF THE TOTAL CANADIAN LIFE SCIENCES ECONOMIC ACTIVITY

49
INCUBATORS AND
ACCELERATORS ACROSS
THE PROVINCE

47 PUBLIC UNIVERSITIES AND COLLEGES PRODUCING

70,000 STEM GRADUATES EACH YEAR

ALMOST 2,000 FIRMS
EMPLOYING MORE THAN
73,000 PEOPLE

\$11.8B OF EXPORTED LIFE SCIENCES GOODS

THE WORLD'S TOP 10
PHARMACEUTICAL
COMPANIES DO CLINICAL
TRIALS HERE

ONTARIO'S EXPERTISE AND LEADERSHIP

The same innovative spirit that led to the discovery of insulin in Ontario decades ago is now leading to game-changing technologies such as 3D bioprinters and techniques to boost stem cell renewal.

- Artificial intelligence
- Biotechnology
- Genomics

- Internet of things
- Medical devices
- Pharmaceuticals





Companies like Roche continue to invest in this vibrant life sciences ecosystem because of the talent here, the collaborative environment, and because there is a deep-seated willingness to work locally and globally to innovate for maximum."

BRIGITTE NOLET

PRESIDENT & CEO, ROCHE CANADA PHARMA

ONTARIO'S VALUE PROPOSITIONS

1. TALENT

74% of working adults possess a post-secondary education





2. INNOVATION ECOSYSTEM

Business, academia and government work together to drive bold ideas to market

3. COMPETITIVE COSTS

Some of the lowest corporate taxes in North America Save up to 50% on after-tax R&D expenditures Source high quality products and services that are extremely cost-competitive





4. ACCESS TO GLOBAL MARKETS

A short distance to U.S. hubs 15 free trade agreements with 51 countries

5. DIVERSITY

People from 150 countries Over 200 languages spoken



WHO'S HERE

- Abbott
- Apotex
- AstraZeneca
- Baxter
- Blue Rock Therapeutics
- Deep Genomics
- GE Healthcare
- GSK
- Johnson & Johnson
- Octane
- Recursion Canada
- Roche
- Sanofi
- Siemens
- Stryker
- Teva
- VBI Vaccines

